Skip to main content

Table 8 Change in HbA1c with DPP-4i use, N = 47 (patients without insulin)

From: Dipeptidyl Peptidase-4 inhibitors use in type II diabetic patients in a tertiary hospital

Type of DPP-4in (%)Pre DPP-4i usePost DPP-4i useMean difference (95% CI)P value£P value¥
Vildagliptin20 (42.6)7.7 ± 0.96.7 ± 0.81.03 (0.37, 1.68)0.004*0.104¢
Sitagliptin13 (27.7)8.8 ± 2.17.1 ± 1.41.69 (0.25, 3.13)0.025*
Saxagliptin13 (27.7)7.8 ± 1.37.4 ± 1.10.32(−0.06, 0.71)0.094
Linagliptin1 (2.1)    
  1. £Paired T-test conducted to compare pre and post DPP-4i HbA1c
  2. ¥ANOVA conducted to compare the HbA1c difference between the groups
  3. Values reported as mean ± SD
  4. *p value is significant at< 0.05
  5. Linagliptin omitted from analysis as n = 1